Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial

CNS Spectrums

Volumn 11, Issue 8, 2006, Pages 625-639

  Weisler, Richard H ^a,b,h   Biederman, Joseph ^c   Spencer, Thomas J ^d   Wilens, Timothy E ^c,d   Faraone, Stephen V ^e   Chrisman, Allan K ^f   Read, Stephanie C ^g   Tulloch, Simon J ^g  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g SHIRE   (United States)

^h Shire Pharmaceuticals Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; CLONIDINE; DOPAMINE; GUANFACINE; NORADRENALIN; PEMOLINE; PLACEBO; STEROID;

ADULT; AGITATION; ANOREXIA; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TACHYCARDIA; THORAX PAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33747380598     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900013687     Document Type: Article

References (42)

1. Barkley RA. Developmental course, adult outcome, and clinic-referred ADHD adults. In: Barkley RA, ed. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York, NY: Guilford Press; 1998:186-224.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.
3. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics. 2000;105:1158-1170.
4. Rowland AS, Umbach DM, Stallone L, Naftel J, Bohlig M, Sandler DP. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health. 2002;92:231-234.
5. Faraone SV, Sergeant J, Gillberg C, Biederman J. The Worldwide Prevalence of ADHD: Is it an American Condition? World Psychiatry. 2003;2:104-113.
6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
7. US Census Bureau Web site. DP-1: Profile of General Demographic Characteristics: 2000. Data set: Census 2000 Summary File 1 (SF 1). Available at: http://factfinder.census.gov/servlet/QTTable?_bm=n&_lang=en&qr_ name=DEC_2000_SF1_U_DP1&ds_name=DEC_2000_SF1_U&geo_ id=01000US. Accessed September 18, 2005.
8. Faraone SV, Spencer TJ, Montano B, Biederman J. Attention-deficit/ hyperactivity disorder in adults. A survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164:1221-1226.
9. Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/ hyperactivity in adults: an overview. Biol Psychiatry. 2000;48:9-20.
10. Hale TS, Hariri AR, McCracken JT. Attention-deficit/hyperactivity disorder: perspectives from neuroimaging. Ment Retard Dev Disabil Res Rev. 2000;6:214-219.
11. Kaplan RF, Stevens M. A review of adult ADHD: a neuropsychological and neuroimaging perspective. CNS Specif. 2002;7:355-353.
12. Biederman J, Mick E, Faraone SV. Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816-818.
13. Millstein RB, Wilens TE, Biederman J, Spencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord. 1997;2:159-166.
14. Weiss G, Hechtman L, Perlman T, Hopkins J, Wener A. Hyperactives as young adults: a controlled, prospective ten-year follow-up of 75 children. Arch Gen Psychiatry. 1979;36:675-681.
15. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50:565-576.
16. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524-540.
17. Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993;92:212-218.
18. Spencer T, Wilens T Biederman J, Faraone SV, Ablon S, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434-443.
19. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775-782.
20. Swanson J. Compliance with stimulants for attention-deficit/hyperactivtty disorder. Issues and approaches for improvement. CNS Drugs. 2003;17:117-131.
21. Jaffe SL. Failed attempts at intranasal abuse of Concerta [letter]. J Am Acad Child Adolesc Psychiatry. 2000;41:5.
22. Comment in: J Am Acad Child Adolesc Psychiatry. 2000;41:756.
23. Castaneda R, Levy R, Hardy M, Trujillo M. Long-acting stimulant for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatr Serv. 2000;51:169-171.
24. Tulloch SJ, Zhang Y, McLean A, Wolf KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22:1405-1415.
25. McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:673-683.
26. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002,110(2 pt 1):258-266.
27. Clausen SB, Read SC, Tulloch SJ: Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr. 2005;10(12 suppl 20):6-15.
28. Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. Rockville, MD: Department of Health and Human Services, Center for Drug Evaluation and Research, Office of Epidemiology Biostatistics; 1995.
29. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.12. Cary, NC: SAS Institute; 1997.
30. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. Epub 2003 Dec 1.
31. Committee for Proprietary Medicinal Products. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London, UK: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, 1997 Dec 17. Report No.: CPMP/986/96.
32. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408-414.
33. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998;94:127-152.
34. Borcherding BG, Keysor CS, Cooper TB, Rapoport JL. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology. 1989;2:255-263.
35. Fischer JF, Cho AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther. 1979;192:642-653.
36. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2004:54:24-29.
37. Wilens TE, Haight BR, Horrigan JR et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57:793-801.
38. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.
39. Spencer T, Muniz R, Kim S, et al. Efficacy of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Poster presented at: annual meeting of the American Psychiatric Association: May 1-6, 2004; New York, NY.
40. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282-288.
41. Adderall XR (package insert). Wayne, Penn: Shire US, Inc.; 2004.
42. Gutgesell H, Atkins D, Barst R, et al. AHA Scientific Statement. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry. 1999;38:1047-1050.